Completed PHASE2 INTERVENTIONAL 1-arm NCT00096031

S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II

Sponsor: National Cancer Institute (NCI)

Interventions cetuximab

Updated 9 times since 2017 Last updated: Aug 29, 2018 Started: Oct 31, 2004 Primary completion: Jan 31, 2008 Completion: Jan 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Esophageal Cancer, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 9 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
May 2023 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — May 2023 [monthly]

Completed PHASE2
Oct 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Aug 2018 — Oct 2018 [monthly]

Completed PHASE2
Jun 2018 — Aug 2018 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
SWOG Cancer Research Network

Data source: SWOG Cancer Research Network

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anchorage, United States , Anderson, United States , Ann Arbor, United States , Asheboro, United States , Asheville, United States , Atlanta, United States , Aurora, United States , Austell, United States , Battle Creek, United States , Bay City, United States and 94 more locations